Which pharmas need a refresh?

Some of the world's richest pharmas are earning the majority of their revenue from drugs that are over 10 years old and heading for patent expiry, but new analysis has exposed which companies have "freshened" their portfolios to replace that income when it disappears.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here